- Home
- NPKI vs TSHA Comparison
NPKI vs TSHA Comparison
Compare NPKI & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPKI
- TSHA
- Stock Information
- Founded
- NPKI 1932
- TSHA 2019
- Country
- NPKI United States
- TSHA United States
- Employees
- NPKI N/A
- TSHA N/A
- Industry
- NPKI Metal Fabrications
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- NPKI Industrials
- TSHA Health Care
- Exchange
- NPKI Nasdaq
- TSHA Nasdaq
- Market Cap
- NPKI 459.3M
- TSHA 397.8M
- IPO Year
- NPKI N/A
- TSHA 2020
- Fundamental
- Price
- NPKI $8.06
- TSHA $2.79
- Analyst Decision
- NPKI Strong Buy
- TSHA Strong Buy
- Analyst Count
- NPKI 1
- TSHA 7
- Target Price
- NPKI $12.00
- TSHA $7.29
- AVG Volume (30 Days)
- NPKI 929.6K
- TSHA 5.0M
- Earning Date
- NPKI 05-01-2025
- TSHA 05-15-2025
- Dividend Yield
- NPKI N/A
- TSHA N/A
- EPS Growth
- NPKI N/A
- TSHA N/A
- EPS
- NPKI N/A
- TSHA N/A
- Revenue
- NPKI $233,299,000.00
- TSHA $7,224,000.00
- Revenue This Year
- NPKI $15.28
- TSHA N/A
- Revenue Next Year
- NPKI $9.62
- TSHA N/A
- P/E Ratio
- NPKI N/A
- TSHA N/A
- Revenue Growth
- NPKI 312.30
- TSHA N/A
- 52 Week Low
- NPKI $4.76
- TSHA $1.05
- 52 Week High
- NPKI $8.66
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- NPKI N/A
- TSHA 62.12
- Support Level
- NPKI N/A
- TSHA $2.44
- Resistance Level
- NPKI N/A
- TSHA $2.95
- Average True Range (ATR)
- NPKI 0.00
- TSHA 0.24
- MACD
- NPKI 0.00
- TSHA -0.02
- Stochastic Oscillator
- NPKI 0.00
- TSHA 55.83
About NPKI NPK International Inc. Common Stock
NPK International Inc Formerly Newpark Resources Inc is a diversified supplier providing environmentally-sensitive products, as well as rentals and services to customers across multiple industries. The company has two operating segments: Industrial Solutions and Fluids Systems. Fluids Systems segment which generates the majority of the revenue, provides drilling, completion, and stimulation fluids products and related technical services to customers for oil, natural gas, and geothermal projects. Geographically, the company derives majority of its revenue from the United States and also has its presence in Canada, EMEA, Latin America, and Asia Pacific regions.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.